An objective of the BIOMUNEX’s strategy aims to establish collaborations and partnerships with major industrial partners either to develop new bi- and multi-specific antibodies using its proprietary BiXAb® platform based on the partner’s existing library or to identify new therapeutically valuable targets, for which BIOMUNEX will generate and optimize bi- or multi-specific antibodies.

BIOMUNEX’s technology will generate antibodies with excellent drug-like properties and high production yields. BIOMUNEX can complete the necessary BiXAb® characterization, design and validation in in vitro and in vivo models and beyond, in order to accommodate partners by taking projects up to regulatory preclinical studies.

The BiXAb® platform has been externally validated by deals with SANOFI and ONWARD Therapeutics: